Pharma Packaging and Labelling Compliance Conference

Fleming Europe23 - 25 March 2011, Barcelona, Spain.
As pharmaceutical and patient landscape is constantly developing worldwide, excellence in strategic packaging and labelling has become essential to regulatory compliance, patient adherence, safety and sustainability.

Fleming Europe has selected from across the globe the highest-level pharmapack specialists, who will share their many market-specific local interpretations, which will influence pharmaceutical packaging and labelling structurally in 2011.

Listen to them speaking about the latest regulations coming into effect in the next months (including PharmaBraille and 2D Datamatrix Marking System). Discover various ways of patient adherence and the business models of in-house vs. outsourced artwork management. Be part of interactive roundtables focusing on the most advanced technologies of pharmapack traceability.…and listen to real-life case studies of anti-counterfeiting, parallel trade and packaging sustanability.

This 3-Day-Event includes a target audience focused post-conference workshop in 2 streams, which will bring together innovative, responsible and cost-effective methods of pharmaceutical and medical packaging, addressing key labelling issues as well as creating partnerships between industry leaders.

Key speakers:

  • Executive Director, Healthcare Compliance Packaging Council (HCPC), Austria
  • Director, Global Regulatory Affairs Strategic Policy & Support, Johnson&Johnson, UK
  • Secretary General, Child-Safe Packaging Group, UK
  • Head of Packaging Strategy, Global Pharma Operations, Novartis, Switzerland
  • Head of Patient Information Quality, MHRA, UK
  • Director of Materials and Packaging Quality System, Eli Lilly, USA
  • Director of Healthcare Traceability, GS1 Global, UK
  • Head of Pharmacy Trade Sector, Roche Diagnostics, Germany

Key topics:

  • Packaging & Labelling Regulatory Updates
  • Patient Adherence
  • Excellence in Artwork Management: In-house vs. Outsourced
  • Traceability to Combat Non-compliance
  • Packaging suitable for the Blind – Braille-Guidelines according to the European standards implemented from October 2010
  • Innovative 2D Datamatrix System for Pharma Traceability
  • Anti-Counterfeiting using Advanced Technology
  • Parallel Traders Perspectives
  • Sustainable Packaging Innovations
  • Child-safe vs. Senior friendly Packaging – Balancing Patients’ Needs
  • Information based Packaging Redesign

Who should attend:
VPs, Directors, Heads and Managers of Packaging, Labelling, Supply Chain and Logistics, Regulatory Affairs and Compliance, Quality Assurance, Product Information, Product Development, Operations, Quality Control and Assurance, Licensing, Marketing and Sales, Patient Compliance, Purchase / Facilities, Manufacturing Technology, International Labelling Liaison, Packaging Designer, Global Labelling.

For further information and registration, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/pharma-packaging-and-labelling-compliance-conference

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...